Compare Cytokinetics Inc (CYTK) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Veritone Inc — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Veritone Inc trades at $0.56 (market cap $59.46M). The key difference: Cytokinetics Inc is far larger — about 145× Veritone Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Veritone Inc for 12 Days on average.
| CYTK | VERI | |
|---|---|---|
Market Cap | $8.62B | $59.46M |
Volume | 2,594,626 | 15,523,164 |
Sector | Health | Technology |
52-Week High | $87.26 | $8.39 |
52-Week Low | $54.76 | $0.59 |
Typical Hold Time | 19 Days | 12 Days |
Enterprise Value | $8.72B | $94.86M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
Veritone (VERI) trades at $0.5851, down 15.36% in the past 24 hours, reflecting significant bearish pressure. The company shows concerning fundamentals with a net income margin of -117.54% and negative ROE of -547.67% for 2025, though it maintains a gross margin of 66.2%. Recent developments include a $15 million equity offering and partnerships with ATP Media and ZeroEyes, while facing securities class action investigations. Technical indicators show mixed signals with bearish moving averages but bullish oscillators.
The outlook remains challenging with persistent losses and negative cash flow from operations, though analyst consensus suggests upside potential with a $3.75 price target. Key risks include ongoing legal scrutiny, execution challenges in achieving profitability, and competitive pressures in the AI solutions space. The stock presents high-risk speculative potential for investors betting on turnaround execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
